T1	Date 70 83	a largo plazo
T2	CHEM 87 97	inclisirán
T3	LIVB 101 114	participantes
T4	DISO 119 162	hipercolesterolemia familiar heterocigótica
T5	DISO 165 206	hipercolesterolemia familiar homocigótica
T6	LIVB 246 258	adolescentes
#1	AnnotatorNotes T6	C0205653; Adolescent (age group); Age Group
T7	Age 246 258	adolescentes
T8	PROC 300 364	Estudio de extensión, multicéntrico, abierto y de un único grupo
T9	PROC 370 409	evaluar la seguridad y la tolerabilidad
T10	Date 410 423	a largo plazo
T11	CHEM 427 437	inclisirán
T12	LIVB 441 454	participantes
T13	DISO 459 517	hipercolesterolemia familiar heterocigótica u homocigótica
T14	LIVB 557 569	adolescentes
#2	AnnotatorNotes T14	C0205653; Adolescent (age group); Age Group
T15	Age 557 569	adolescentes
T16	DISO 625 653	Hipercolesterolemia familiar
#3	AnnotatorNotes T16	C0020445; Hypercholesterolemia, Familial; Disease or Syndrome
T17	LIVB 681 709	Participantes de ambos sexos
T18	PROC 717 728	diagnóstico
#4	AnnotatorNotes T18	C0011900; Diagnosis; Diagnostic Procedure
T19	DISO 732 736	HFHe
T20	DISO 739 743	HFHo
T21	CHEM 859 866	fármaco
#5	AnnotatorNotes T21	C0013227; Pharmaceutical Preparations; Pharmacologic Substance
T22	PROC 901 907	visita
T23	PROC 935 944	protocolo
#6	AnnotatorNotes T23	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T24	LIVB 994 1006	investigador
#7	AnnotatorNotes T24	C0035173; Research Personnel; Professional or Occupational Group
T25	LIVB 1012 1025	participantes
T26	PROC 1056 1067	tratamiento
#8	AnnotatorNotes T26	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T27	CHEM 1072 1082	inclisirán
T28	Date 1143 1159	en la actualidad
T29	PROC 1160 1188	tratamientos hipolipemiantes
T30	CHEM 1198 1207	estatinas
#9	AnnotatorNotes T30	C0075191; statine; Amino Acid, Peptide, or Protein | C0360714; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Organic Chemical · Pharmacologic Substance
T31	CHEM 1210 1219	ezetimiba
#10	AnnotatorNotes T31	C1142985; ezetimibe; Organic Chemical · Pharmacologic Substance
T32	Neg_cue 1243 1253	sin ningún
T33	Negated 1254 1301	cambio previsto en la medicación ni en la dosis
T34	CHEM 1276 1286	medicación
#11	AnnotatorNotes T34	C0013227; Pharmaceutical Preparations; Pharmacologic Substance
T35	LIVB 1370 1383	Participantes
T36	CHEM 1451 1461	inclisirán
T37	PROC 1510 1554	discontinuado permanentemente el tratamiento
T38	DISO 1612 1657	problemas graves de seguridad o tolerabilidad
T39	PROC 1678 1689	tratamiento
#12	AnnotatorNotes T39	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T40	CHEM 1694 1704	inclisirán
T41	DISO 1718 1728	enfermedad
#13	AnnotatorNotes T41	C0012634; Disease; Disease or Syndrome | C0221423; Illness (finding); Sign or Symptom
T42	Neg_cue 1729 1731	no
T43	Negated 1732 1742	controlada
T44	DISO 1764 1801	condición médica, física o quirúrgica
T45	Spec_cue 1806 1811	pueda
T46	Speculated 1812 1822	interferir
T47	PROC 1849 1864	estudio clínico
#14	AnnotatorNotes T47	C0008972; Clinical Research; Research Activity | C0008976; Clinical Trials; Research Activity
T48	Speculated 1935 1941	riesgo
T49	LIVB 1964 1976	participante
T50	DISO 1980 1999	Enfermedad hepática
#15	AnnotatorNotes T50	C0023895; Liver diseases; Disease or Syndrome
T51	DISO 2031 2076	patología infecciosa, neoplásica o metabólica
T52	Date 2077 2083	actual
T53	ANAT 2088 2094	hígado
#16	AnnotatorNotes T53	C0023884; Liver; Body Part, Organ, or Organ Component | C1278929; Entire liver; Body Part, Organ, or Organ Component
